Article

USPSTF Advises Against Routine Ovarian Cancer Screening

US Preventive Services Task Force states that screening tests for ovarian cancer are often inaccurate.

Women who have no signs or symptoms of ovarian cancer should not receive a screening, according to a draft recommendation statement from the US Preventive Services Task Force (USPSTF).

While ovarian cancer is the fifth most common cause of cancer death among American women, a review of evidence shows that screening tests for ovarian cancer are often inaccurate.

These incorrect diagnoses can lead to unnecessary surgeries to remove the ovaries and fallopian tubes, according to the statement. There are no American medical organizations that recommend ovarian cancer screenings for all women.

“The current screening tests do not do a good job identifying whether a woman does or does not have ovarian cancer. The Task Force hopes that in the future, better screening tests for ovarian cancer will be developed,” Task Force chair David Grossman, MD, MPH noted in the USPSTF Bulletin about the statement.

The recommendation is only for asymptomatic women who are not at higher risk of developing ovarian cancer, according to the statement, and would not apply to women at higher risk, such as those who have certain mutations, like BRCA.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards